SPARCSun Pharma Advanced Research Company Ltd.
Sun Pharma Advanced Research Company Q2 FY27 Results: Consolidated Net Loss ₹24.39 Crore on Total Income of ₹53.65 Crore
- Earnings
- pharmaceutical research and development
Reviewed byRachit TripathiBlacklitt Research
Sun Pharma Advanced Research Company (NSE: SPARC) reported consolidated total income of ₹53.65 crore and a net loss of ₹24.39 crore for the quarter ended 30 Sep 2026, as stated in its filing of 02 Nov 2026. Standalone total income was the same at ₹53.65 crore, with a net loss of ₹24.58 crore.
Key highlights
Consolidated
Including its subsidiaries
- Total income: ₹53.65 crore, down 15.6% QoQ and up 581.7% YoY
- Net profit and EPS: Net loss of ₹24.39 crore; loss attributable to owners ₹25.96 crore; EPS -₹0.64
- Other income: ₹23.62 crore, against revenue from operations of ₹30.03 crore
- Finance costs: ₹0.12 crore, against ₹8.13 crore in the quarter ended 30 Jun 2026
Standalone
The company on its own, without its subsidiaries
- Total income: ₹53.65 crore, down 15.6% QoQ and up 581.7% YoY
- Net profit and EPS: Net loss of ₹24.58 crore; EPS -₹0.65
- Other income: ₹23.62 crore, against revenue from operations of ₹30.03 crore
- Finance costs: ₹0.12 crore, against ₹8.13 crore in the quarter ended 30 Jun 2026
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 54 | 8 | +581.7% | 64 | -15.6% | |
| Revenue from operations | 30 | 8 | +282.1% | 40 | -24.8% |
| Other income | 24 | 0 | n/a | 24 | -0.2% |
| -24 | -76 | +67.8% | -21 | -17.4% | |
| Profit before tax | -24 | -76 | +67.9% | -21 | -17.6% |
| Finance costs | 0 | 8 | -98.4% | 8 | -98.5% |
| Depreciation | 2 | 3 | -14.1% | 2 | 0.0% |
| Tax expense | 0 | 0 | +33.3% | 0 | -27.3% |
| Net profit margin | -45.46% | -963.79% | +918.33 pp | -32.68% | -12.78 pp |
| EPS, basic (₹) | -0.64 | -2.34 | +72.6% | -0.75 | +14.7% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Revenue from operations fell from ₹39.92 crore in the quarter ended 30 Jun 2026 to ₹30.03 crore, while other income held near ₹24 crore, so other income now makes up a large share of the total. The notes say the previous quarter included ₹29.21 crore of revenue recognised on the termination of a licensing agreement with CMS Bridging DMCC.
Finance costs were ₹0.12 crore, or 0.2% of total income, against ₹8.13 crore a quarter earlier and ₹7.52 crore a year earlier. Tax expense was ₹8 lakh on a pre-tax loss of ₹24.31 crore, so the net loss is slightly larger than the pre-tax loss.
The loss attributable to owners of ₹25.96 crore is ₹1.57 crore more than the net loss for the period of ₹24.39 crore. The statement's other comprehensive income lines are an actuarial loss of ₹1.64 crore on employee benefits and an exchange gain of ₹0.07 crore.
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 54 | 8 | +581.7% | 64 | -15.6% | |
| Revenue from operations | 30 | 8 | +282.1% | 40 | -24.8% |
| Other income | 24 | 0 | n/a | 24 | -0.2% |
| -25 | -76 | +67.6% | -21 | -17.2% | |
| Profit before tax | -25 | -76 | +67.6% | -21 | -17.2% |
| Finance costs | 0 | 8 | -98.4% | 8 | -98.5% |
| Depreciation | 2 | 3 | -14.4% | 2 | 0.0% |
| Tax expense | 0 | 0 | n/a | 0 | n/a |
| Net profit margin | -45.82% | -965.31% | +919.50 pp | -33.00% | -12.82 pp |
| EPS, basic (₹) | -0.65 | -2.34 | +72.2% | -0.76 | +14.5% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
The standalone net loss of ₹24.58 crore is ₹0.19 crore larger than the consolidated net loss of ₹24.39 crore, and the standalone EPS of -₹0.65 is marginally lower than the consolidated -₹0.64. Standalone revenue from operations and other income match the consolidated lines, and no tax expense is recorded.
Inference
The filing says 25% of the issue price was received on allotment, and the balance of ₹116.85 per warrant is payable within 18 months, at the time of exercise.
The notes say the previous year's income included ₹1,840.02 crore from a USFDA Priority Review Voucher for Sezaby, which the company sold on 30 Apr 2026 for USD 195 million. The filing does not say how the warrant proceeds will be used, or when the warrants will be converted.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
